Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19348913.
- Also identified by DOI 10.1016/j.jaci.2009.03.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Forkhead box protein 3-positive regulatory T (Treg) cells are indispensable for the maintenance of self-tolerance and immune homeostasis. They can also be exploited for the treatment of immunologic diseases, including autoimmune diseases and allergy, by way of activating and expanding antigen-specific Treg cells in vivo. Cell therapy with in vitro activated and expanded Treg cells can be another therapeutic modality. The feasibility of such Treg cell-based therapeutic strategies is discussed based on recent advances in our understanding of the molecular and cellular basis of Treg cell development and function.
Medical subject headings
- Autoimmunity
- Forkhead Transcription Factors
- Hypersensitivity
- Lymphocyte Activation
- T-Lymphocytes, Regulatory